Hong Ding, MD, PhD
Hong Ding, MD, PhD
Associate Professor of Research in Pharmacology

Phone: (+974) 4492 8362
Hong Ding, MD, PhD

PROFILE

Dr. Ding joined Weill Cornell Medicine - Q (WCM-Q) in October 2007 and is actively and enthusiastically involved in biomedical research and teaching of pharmacology to 1st and 2nd year medical students. Dr. Ding obtained her M.D. degree from Zhejiang University in China and worked as a physician in Hangzhou Hospital for four years before moving to Canada. Dr. Ding obtained a Ph.D. in Cardiovascular Pharmacology from the University of Calgary in Canada, where she also undertook post-doctoral training. After additional postdoctoral work at the University of Ottawa in Canada and Yale University in the U.S., she joined the faculty in the Department of Medical Sciences and Microvascular Research Group at RMIT University in Melbourne, Australia, where she pursued studies of microvascular disease in diabetes.

Dr. Ding continues to pursue her research interests in the area of vascular disease and diabetes through collaborations with Dr. Triggle (WCM-Q), Dr. Tuana (University of Ottawa), Drs. Vanhoutte & Xu (University of Hong Kong), Dr. Barritt (Flinders University), Dr. Hill (University of Missouri), Dai (China Pharmaceutical University), Drs. Garland and Dora (University of Oxford).

SELECTED PUBLICATIONS
  • Arunachalam G, Lakshmanan AP, Samuel SM, Triggle CR, Ding H. Molecular interplay between microRNA-34a and sirtuin1 in hyperglycaemia-mediated impaired angiogenesis in endothelial cells: Effects of metformin. J. Pharmacol. Exp Ther. J Pharmacol Exp Ther. 2016 Feb;356(2):314-23.
  • Triggle CR, Ding H. Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium. Acta Physiol (Oxf). 2015 Dec 17.
  • Ghosh S, Lakshmanan AP, Hwang MJ, Kubba H, Mushannen A, Triggle CR, Ding H. Metformin improves endothelial function in aortic tissue and microvascular endothelial cells subjected to diabetic hyperglycaemic conditions. Biochem Pharmacol. 2015 Dec 1;98(3):412-21.
  • Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y, Jin L, Lian Q, Huang Y, Ding H, Triggle C, Wang K, Li X, Xu A. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation. 2015 May 26;131(21):1861-71.
  • Kinaan M, Ding H, Triggle CR. Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for Protection of the Endothelium. Med Princ Pract. 2015;24(5):401-15.
  • Arunachalam G, Upadhyay R, Ding H, Triggle CR. MicroRNA signature and cardiovascular dysfunction. J Cardiovascular Pharmacology. J Cardiovasc Pharmacol. 2015 May;65(5):419-29
  • Upadhyay R, Robay A, Fakhro K, Abi Khalil C, Zirie M, Jayyousi A, El-Shafei M, Kiss S, D'Amico DJ, Salit J, Staudt MR, O'Beirne SL, Chen X, Tuana B, Crystal RG, Ding H. Role of SLMAP genetic variants in susceptibility of diabetes and diabetic retinopathy in Qatari population. J Transl Med. 2015 Feb 15;13:61.
  • Liang Q, Zhong L, Zhang J, Wang Y, Bornstein SR, Triggle CR, Ding H, Lam KS, Xu A. FGF21 Maintains Glucose Homeostasis by Mediating the Cross Talk Between Liver and Brain During Prolonged Fasting. Diabetes. 2014 Dec;63(12):4064-75.
  • Triggle CR, Ding H. The cardiovascular impact of diabetes drugs. Ther Adv Chronic Dis. 2014 Nov;5(6):245-68.
  • Arunachalam G, Samuel SM, Marei I, Ding H, Triggle CR. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol. 2014 Jan;171(2):523-35



Last modified on Thursday, 02-Jun-2016 13:27:29 +03